November 2013

ChartTrends®: Systemic Lupus Erythematosus (US) 2013


This report is an annual publication that provides comprehensive insight into the management of systemic lupus erythematosus (SLE) patients being treated with immunosuppressants, corticosteroids, anti-malarials and biologics based on actual patient-level data.
ChartTrends® are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific moderate-to-severe SLE patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

Questions Answered in This Report:

  *   Quantify SLE patient load and distribution by severity and disease clinical manifestation.

  *   Understand the demographics of SLE patients including diagnosis, comorbidities and flares experienced within past 12 months.

  *   Understand the standard of care for SLE patients including the use and frequency of laboratory assessments.

  *   Assess the SLE treatment approach and reasons for product selection.

  *   Identify the typical patient profile for each drug class/brand (line of therapy, length of therapy, dosing, discontinuation rates, organ system involvement, co-morbidities, patient demographics, average number of flares per year, ability to achieve remission).

  *   Identify the typical patient profile for each clinical manifestation (i.e. renal, CNS, derm).

  *   Evaluate physician awareness and receptivity to late stage products in development for SLE.


Sample Methodology:

The ChartTrends® study is comprised of:

- A physician profile for demographics and attitudinal segmentation

- A patient record audit for lab and demographic values, product usage

- 200+ rheumatologists will complete patient audits for five to eight of their moderate-to-severe SLE patients (1,000+ SLE patient audits in total) who are being treated with immunosuppressive, corticosteroid, anti-malarial and biologic agents.

- Participants will complete the profile survey and patient audits online.

- The audit is HIPAA-compliant.


- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics and standard cross tabulations

- Database containing de-identified patient audit data in SPSS and/or Excel

- Proprietary question slide deck: Clients purchasing report prior to fielding have the opportunity to include up to three proprietary questions in the Physician Profile Section

Key Drugs Covered:

- azathioprine, Benlysta, cyclophospha-mide, CellCept/Myfortic, hydroxychlo-roquine, methotrexate, Orencia, Rituxan, atacicept, blisibimod, epratuzumab, rigerimod and tabalumab

Report Dates:

- Publish: November 18, 2013

Physician Research:

- 200+ rheumatologists will complete patient audits for 1,000+ SLE patients


- United States

Key Companies Mentioned:

- Anthera

- Bristol-Myers Squibb

- Eli Lilly

- EMD Serono

- Genentech

- Immupharma

- UCB Pharmaceuticals

Content Highlights:

- HIPAA-certified patient demographics

- HIPAA-certified patient history: Referral, Diagnoses, Co-morbidities

- Insurance coverage

- Medication lists: Dose, Delivery/formulation, First-prescribed

- Treatment history: Product switches, dose adjustments, adjunctive Therapies

- Laboratory results: Frequency of testing and Lab values

- Integrated with respondent demographics and attitudinal variables to understand physi-cian segments

Related Reports:

- TreatmentTrends®: SLE (EU)

- TreatmentTrends®: SLE (US)

- DecisionBase®: SLE (Moderate to Severe)

- Pharmacor®: SLE

Fill out the form below to contact sales.

Search Reports

Decision Resources Group brands include: